These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 1732982)

  • 1. Receptor-directed contrast agents for MR imaging: preclinical evaluation with affinity assays.
    Reimer P; Weissleder R; Wittenberg J; Brady TJ
    Radiology; 1992 Feb; 182(2):565-9. PubMed ID: 1732982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors.
    Weissleder R; Reimer P; Lee AS; Wittenberg J; Brady TJ
    AJR Am J Roentgenol; 1990 Dec; 155(6):1161-7. PubMed ID: 2122660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor imaging: application to MR imaging of liver cancer.
    Reimer P; Weissleder R; Lee AS; Wittenberg J; Brady TJ
    Radiology; 1990 Dec; 177(3):729-34. PubMed ID: 2243978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats.
    Leveille-Webster CR; Rogers J; Arias IM
    Hepatology; 1996 Jun; 23(6):1631-41. PubMed ID: 8675187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging.
    Reimer P; Weissleder R; Lee AS; Buettner S; Wittenberg J; Brady TJ
    Radiology; 1991 Mar; 178(3):769-74. PubMed ID: 1994416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo hepatocyte MR imaging using lactose functionalized magnetoliposomes.
    Ketkar-Atre A; Struys T; Dresselaers T; Hodenius M; Mannaerts I; Ni Y; Lambrichts I; Van Grunsven LA; De Cuyper M; Himmelreich U
    Biomaterials; 2014 Jan; 35(3):1015-24. PubMed ID: 24210051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MION-ASF: biokinetics of an MR receptor agent.
    Schaffer BK; Linker C; Papisov M; Tsai E; Nossiff N; Shibata T; Bogdanov A; Brady TJ; Weissleder R
    Magn Reson Imaging; 1993; 11(3):411-7. PubMed ID: 7685055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
    Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
    Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of hepatocellular carcinomas from hyperplastic nodules induced in rat liver with ferrite-enhanced MR imaging.
    Kawamori Y; Matsui O; Kadoya M; Yoshikawa J; Demachi H; Takashima T
    Radiology; 1992 Apr; 183(1):65-72. PubMed ID: 1549696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benign hepatic tumors: MRI features before and after administration of superparamagnetic contrast media].
    Bartolotta TV; Midiri M; Galia M; Carcione A; De Maria M; Lagalla R
    Radiol Med; 2001 Apr; 101(4):219-29. PubMed ID: 11398050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver.
    Stark DD; Weissleder R; Elizondo G; Hahn PF; Saini S; Todd LE; Wittenberg J; Ferrucci JT
    Radiology; 1988 Aug; 168(2):297-301. PubMed ID: 3393649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of magnetic resonance in characterizing focal liver lesions].
    Colagrande S; Bartolozzi A; Tonarelli A
    Radiol Med; 1994 Apr; 87(4):469-81. PubMed ID: 8190931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical assessment of hepatocyte-targeted MR contrast agents in stable human liver cell cultures.
    Reimer P; Bader A; Weissleder R
    J Magn Reson Imaging; 1998; 8(3):687-9. PubMed ID: 9626887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Magnetic resonance tomography of focal liver and spleen lesions. Experiences using ferrite, a new RES-specific MR contrast medium].
    Rummeny E; Weissleder R; Stark DD; Elizondo G; Ferrucci JT
    Radiologe; 1988 Aug; 28(8):380-6. PubMed ID: 3174975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of MR relaxation effects of iron oxide particles in liver and spleen.
    Majumdar S; Zoghbi S; Pope CF; Gore JC
    Radiology; 1988 Dec; 169(3):653-8. PubMed ID: 3186986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of hepatic metastases from colorectal carcinoma with MR-superparamagnetic iron oxide.
    Vidiri A; Carpanese L; Annibale MD; Caterino M; Cosimelli M; Zeuli M; David V; Crecco M
    J Exp Clin Cancer Res; 2004 Mar; 23(1):53-60. PubMed ID: 15149151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR imaging in the evaluation of hepatic metastases.
    Imam K; Bluemke DA
    Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):741-56. PubMed ID: 11149677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferrite-enhanced MR imaging of hepatic lymphoma: an experimental study in rats.
    Weissleder R; Stark DD; Compton CC; Wittenberg J; Ferrucci JT
    AJR Am J Roentgenol; 1987 Dec; 149(6):1161-5. PubMed ID: 3318339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging.
    Weissleder R; Hahn PF; Stark DD; Elizondo G; Saini S; Todd LE; Wittenberg J; Ferrucci JT
    Radiology; 1988 Nov; 169(2):399-403. PubMed ID: 3174987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular magnetic resonance imaging with targeted contrast agents.
    Artemov D
    J Cell Biochem; 2003 Oct; 90(3):518-24. PubMed ID: 14523986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.